A 24-week treatment with bofanglutide for patients with type 2 diabetes showed meaningful glycemic control, weight loss, and improvements in cardiometabolic risk factors — reductions which seemed at ...

HHS terminates COVID-19 Emergency Use Authorizations for drugs, biologics, and devices, establishing transition timelines toward traditional FDA pathways.

Metformin does not significantly reduce the risk for long COVID at 6 months in low-risk adults with high baseline immunity to the virus.

Survivors of hematologic cancers face a higher risk of developing cardiovascular disease, according to study results.

Better maternal CVH is associated with lower risk for offspring developmental delay at age 4 years, according to study results.

Younger adults are more susceptible to asymptomatic rhinovirus infections, whereas older adults are more likely to experience respiratory symptoms.

A surge in tetracycline resistance reduces the clinical benefit of doxycycline PEP against gonorrhea in high-risk populations.

The CDC released updated operational guidance for investigating locally-acquired mosquito-transmitted malaria in the US.

An FDA panel voted 9-0 that the benefits of Moderna’s mRNA-1010 flu vaccine outweigh risks for adults aged 50 and older.

Genetically predicted lower systolic blood pressure is associated with an increased susceptibility to allergic rhinitis.

Among patients with IDU-related IE, initiation of MOUD is associated with a significant reduction in 30-day all-cause mortality, though optimizing care delivery models remains essential for sustaining ...

Metformin use may lower the risk for a composite of hospitalization, ED visits, or death in adult patients with acute COVID-19.